Demir Bahar, Mishra Amit, Gutierrez Maria Pilar Martin, Rasheed Rajna, Charitaki Maria, Preston Ella, Sivaprasad Sobha, Hykin Philip, Nicholson Luke
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
Can J Ophthalmol. 2024 Aug;59(4):275-278. doi: 10.1016/j.jcjo.2023.07.004. Epub 2023 Jul 27.
To report the visual outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment for macular edema secondary to central retinal vein occlusion (CRVO) in patients with baseline visual acuity of ≤23 ETDRS letters vision.
Retrospective observational cohort study.
This is a single-institution study. A total of 173 eyes from 173 patients who had completed 3 consecutive monthly anti-VEGF injections for macular edema secondary CRVO and best-corrected visual acuity (BCVA) ≤23 ETDRS letters were included. The main outcome measures were visual acuity at month 3 and month 12.
At month 3, BCVA increased to 34.1 ETDRS letters (95% CI, 30.7-37.5), with a gain of 25.0 letters (95% CI, 22.0-28.5; p < 0.001). The mean central subfield thickness decreased by 519 μm (95% CI, 475.5-567.0; p < 0.001). Most patients (67.6%) gained >15 ETDRS letters. A total of 160 patients were followed up for 12 months, and the mean BCVA was 31.2 ETDRS letters (95% CI, 27.5-34.9) at the end of this period. A third of eyes that did not respond (<5-letter gain) after a single injection experienced a 15-letter or more improvement after 3 consecutive injections.
Anti-VEGF treatment in eyes with CRVO and poor baseline visual acuity results in significant visual improvement, and moderate improvement is still noted despite a poor response after a single injection.
报告玻璃体内注射抗血管内皮生长因子（抗VEGF）治疗基线视力≤23个ETDRS字母的视网膜中央静脉阻塞（CRVO）继发黄斑水肿患者的视力结果。
回顾性观察队列研究。
本研究为单机构研究。纳入了173例患者的173只眼，这些患者因CRVO继发黄斑水肿连续3个月每月接受一次抗VEGF注射，且最佳矫正视力（BCVA）≤23个ETDRS字母。主要观察指标为第3个月和第12个月时的视力。
第3个月时，BCVA提高至34.1个ETDRS字母（95%CI，30.7 - 37.5），提高了25.0个字母（95%CI，22.0 - 28.5；p<0.001）。平均中心子野厚度降低了519μm（95%CI，475.5 - 567.0；p<0.001）。大多数患者（67.6%）提高超过15个ETDRS字母。共有160例患者随访12个月，在此期间结束时平均BCVA为31.2个ETDRS字母（95%CI，27.5 - 34.9）。单次注射后无反应（提高<5个字母）的眼睛中有三分之一在连续3次注射后提高了15个字母或更多。
CRVO且基线视力差的眼睛接受抗VEGF治疗可显著改善视力，尽管单次注射后反应不佳，但仍有中度改善。
